Author:
Ord J J,Streeter E,Jones A,Le Monnier K,Cranston D,Crew J,Joel S P,Rogers M A,Banks R E,Roberts I S D,Harris A L
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Bikfalvi A, Sauzeau C, Moukadiri H, Maclouf J, Busso N, Bryckaert M, Plouet J, Tobelem G (1991) Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects. J Cell Physiol 149: 50–59
2. Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR (1996) A phase I/II study of continuous infusion Suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol 39: 1–8
3. Brekken RA, Huang X, King SW, Thorpe PE (1998) Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58: 1952–1959
4. Chalkley H (1943) Methods for the quantitative morphological analysis of tissues. J Natl Cancer Inst 4: 47–53
5. Coffey Jr RJ, Leof EB, Shipley GD, Moses HL (1987) Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 132: 143–148
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献